Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vaginal polymicrobial biofilms are dense, structured microbial communities primarily composed of Gardnerella vaginalis and various anaerobic species, such as Atopobium vaginae and Prevotella, which adhere to the vaginal epithelium (Swidsinski et al., 2005). These biofilms are encased in a protective extracellular polymeric substance (EPS) matrix that facilitates bacterial persistence by providing a physical barrier against host immune defenses and antimicrobial agents (Machado et al., 2015). As the hallmark of bacterial vaginosis (BV), these biofilms are responsible for the characteristic clue cells observed in clinical diagnostics and are strongly linked to the high rates of treatment failure and recurrence (Muzny et al., 2019). The biofilm structure allows for synergistic interactions between different bacterial species, enhancing their collective resistance to standard antibiotic therapies like metronidazole (Cerca et al., 2022). Effective management of BV increasingly requires therapeutic strategies that specifically target the biofilm architecture, such as the use of boric acid or specialized antiseptics, to disrupt the EPS and allow for the eradication of sequestered pathogens. Understanding the dynamics of these biofilms is crucial for developing treatments that can successfully restore the healthy, Lactobacillus-dominant vaginal environment and prevent complications like preterm birth or increased susceptibility to sexually transmitted infections.
Drugs targeting these biofilms typically employ mechanisms such as the chemical disruption of the EPS matrix (e.g., boric acid), enzymatic degradation of biofilm components (e.g., DNase), or the use of broad-spectrum antiseptics like dequalinium chloride that penetrate the biofilm more effectively than traditional antibiotics (Machado et al., 2015; Gottschick et al., 2017). Additionally, some therapies aim to prevent the initial adhesion of Gardnerella vaginalis to the vaginal mucosa, thereby inhibiting the formation of the biofilm scaffold (Cerca et al., 2022).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vaginal polymicrobial biofilm.